Dr. Ruowen Ge

Ruowen Ge obtained her BSc in Genetics from Nankai University, China; PhD in Molecular Cell Biology from University of Pennsylvania, USA. After postdoctoral trainings at Lederle Laboratories (now Pfizer) and Roche Institute of Molecular Biology (Roche), she joined National University of Singapore as assistant professor in 1996 and became a tenured associate professor in 2003. Her research interests are anti-angiogenic, anti-cancer and anti-inflammation proteins/peptides, and their biomedical applications. She has published 86 peer-reviewed papers, filed 10 patent applications with 3 already awarded. Her lab has discovered 3 novel endogenous anti-angiogenic proteins (ISM1, ADAMTS4 and ADAMTS5), and a novel anti-inflammatory protein with potential as a first-in-class therapeutic for chronic obstructive lung disease (COPD) (patent pending). She is a scientific co-founder of the biopharma company ProTherapeutics Pte Ltd.